MARKET

CRNX

CRNX

Crinetics Pharmaceuticals
NASDAQ
47.96
-0.75
-1.54%
After Hours: 47.96 0 0.00% 17:38 12/26 EST
OPEN
48.26
PREV CLOSE
48.71
HIGH
48.41
LOW
47.80
VOLUME
416.85K
TURNOVER
--
52 WEEK HIGH
54.78
52 WEEK LOW
24.10
MARKET CAP
4.55B
P/E (TTM)
-10.5807
1D
5D
1M
3M
1Y
5Y
1D
Crinetics Pharmaceuticals (CRNX): Assessing Valuation After a 36% Three-Month Share Price Rebound
Simply Wall St · 4d ago
Weekly Report: what happened at CRNX last week (1215-1219)?
Weekly Report · 5d ago
Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
Reuters · 12/18 21:05
Crinetics drops 9% after executive Dana Pizzuti steps down
TipRanks · 12/18 17:25
Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference
Barchart · 12/18 15:05
Evercore ISI Reaffirms Their Buy Rating on Crinetics Pharmaceuticals (CRNX)
TipRanks · 12/18 11:56
Crinetics Pharmaceuticals Grants $577,000 Severance and Bonus Eligibility to Departing Chief Medical Officer
Reuters · 12/17 22:00
Will Crinetics’ (CRNX) First SST2 NDC Trial and Atumelnant Milestone Reframe Its Pipeline Narrative?
Simply Wall St · 12/16 07:13
More
About CRNX
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.

Webull offers Crinetics Pharmaceuticals Inc stock information, including NASDAQ: CRNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRNX stock methods without spending real money on the virtual paper trading platform.